Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) have received a consensus rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $30.51.

Several brokerages recently weighed in on RDY. Jefferies Group LLC cut their target price on Dr. Reddy’s Laboratories from $31.62 to $30.51 and set an “underperform” rating on the stock in a research report on Wednesday, November 1st. Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 26th. Morgan Stanley upgraded Dr. Reddy’s Laboratories from an “equal weight” rating to an “overweight” rating in a report on Thursday, September 21st. CLSA upgraded Dr. Reddy’s Laboratories from an “underperform” rating to an “outperform” rating in a report on Thursday, August 31st. Finally, BidaskClub downgraded Dr. Reddy’s Laboratories from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th.

COPYRIGHT VIOLATION NOTICE: “Dr. Reddy’s Laboratories Ltd (RDY) Receives Consensus Recommendation of “Hold” from Brokerages” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/17/dr-reddys-laboratories-ltd-rdy-receives-consensus-recommendation-of-hold-from-brokerages.html.

Dr. Reddy’s Laboratories (NYSE:RDY) opened at $35.67 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.46 and a quick ratio of 1.08. The firm has a market capitalization of $5,850.00, a price-to-earnings ratio of 34.45, a P/E/G ratio of 10.37 and a beta of 0.41. Dr. Reddy’s Laboratories has a 52-week low of $29.83 and a 52-week high of $47.75.

Several institutional investors have recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Dr. Reddy’s Laboratories by 0.4% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 14,160 shares of the company’s stock valued at $582,000 after acquiring an additional 60 shares in the last quarter. Profund Advisors LLC grew its stake in shares of Dr. Reddy’s Laboratories by 5.2% during the second quarter. Profund Advisors LLC now owns 11,832 shares of the company’s stock valued at $499,000 after acquiring an additional 580 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Dr. Reddy’s Laboratories by 11.7% during the second quarter. Ameriprise Financial Inc. now owns 10,087 shares of the company’s stock valued at $426,000 after acquiring an additional 1,054 shares in the last quarter. Alliancebernstein L.P. grew its stake in Dr. Reddy’s Laboratories by 16.4% in the second quarter. Alliancebernstein L.P. now owns 9,085 shares of the company’s stock worth $383,000 after purchasing an additional 1,277 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Dr. Reddy’s Laboratories in the second quarter worth about $144,000. Institutional investors own 15.11% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Receive News & Stock Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related stocks with our FREE daily email newsletter.